drugsTreatmentPhase 3

Visugromab

Visugromab is CatalYm's antibody against GDF-15, a tumour-made signal that both blocks immune cells and causes cancer wasting; it is in a phase 3 trial with PD-1 blockade after durable responses in patients whose cancers had stopped responding to checkpoint inhibitors.

CatalYm, a Munich biotech, developed visugromab (CTL-002) after showing that GDF-15 secreted by tumours prevents T cells from entering them. In the GDFATHER trials it produced durable responses with nivolumab in patients with checkpoint-refractory cancers, and the same molecule is being studied for cancer-associated cachexia, since GDF-15 acts on the brainstem to suppress appetite. A phase 3 trial is registered.

Schematic of the modality · Anti-GDF-15 monoclonal antibody, intravenous · not a molecule; see the Immune checkpoint inhibitors page

See it in action

Neutralises growth differentiation factor 15, a cytokine many tumours secrete that keeps T cells out of the tumour and drives cachexia; blocking it is meant to restore immune infiltration and reverse weight loss.

1. What happens next: the antibody schematic

How it works, step by step · animated schematic, not to scale

Immune checkpoint inhibitors →

2. Step by step

auto-advancing · hover to pause

1.Visugromab binds its target.

Modality

Anti-GDF-15 monoclonal antibody, intravenous

Mechanism

Brand / code

CTL-002

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Visugromab

intervention: Visugromab

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.